CNS vs NRXP: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
CNS and NRXP are similarly sized, but NRXP trades noticeably cheaper on forward earnings (6.30x vs 21.15x): the market is paying up for CNS's profile and pricing NRXP more conservatively, or for faster growth. Which you prefer comes down to the drivers you believe, and whether adding either over-concentrates what you already own.
CNS vs NRXP: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | CNS | NRXP | What it tells you |
|---|---|---|---|
| Forward P/E | 21.15 | 6.30 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 1.22 | 2.19 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 90% of range | 45% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Reading it: NRXP is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how CNS and NRXP affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CNS and NRXP share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CNS and NRXP exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Cohen & Steers (CNS) do?
Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. It organized the first US real estate securities mutual fund and remains one of the largest managers of REIT securities in the world, with roughly two-thirds of assets in listed real estate. The firm earns management fees on the assets it runs across open-end funds, closed-end funds, institutional accounts, and newer vehicles like its non-traded REIT (CNSREIT).
What does NRx Pharmaceuticals (NRXP) do?
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company targeting central nervous system and psychiatric conditions, with an emphasis on the NMDA receptor pathway. Its lead assets are NRX-100, a preservative-free intravenous ketamine that has received Fast Track designation for suicidal ideation in depression including bipolar depression, and NRX-101, an oral D-cycloserine and lurasidone combination that has received Breakthrough Therapy designation for suicidal bipolar depression and is also being explored as an adjunct to transcranial magnetic stimulation. The company has pursued an ANDA pathway for its preservative-free ketamine (marketed under the KETAFREE name), with an FDA decision anticipated in 2026.
CNS vs NRXP: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- CNS drivers: Rate-cut tailwind for real assets; Return to organic growth.
- NRXP drivers: Preservative-free ketamine FDA decision; NRX-101 in suicidal bipolar depression.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: CNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings. For NRXP, nRXP is a speculative, cash-constrained clinical-stage biotech with minimal product revenue and a history of net losses.
CNS or NRXP: which should you pick?
CNS vs NRXP: the full fundamentals
CNS. As of April 2026, CNS traded around a mid-20s price-to-earnings multiple with a dividend yield near 3.7%, reflecting its status as a profitable, dividend-paying specialty manager. Q1 2026 revenue of about $145.6 million grew roughly 8% year over year, and operating margin improved to about 34%. Because fees scale with AUM, valuation and earnings hinge on the direction of markets and flows into real-asset strategies.
NRXP. All figures here are approximate and qualitative. A clinical-stage biotech's cash position, share count, pipeline status, and regulatory timelines change frequently, sometimes on short notice. Verify the latest numbers from NRx filings, its investor relations releases, and a live quote before making any decision.
Headline figures (approximate, APRIL 2026): CNS shows assets under management ~$93.1B, revenue (q1 2026) ~$145.6M, q1 2026 net inflows ~$497M, diluted eps (q1 2026) ~$0.82; NRXP shows revenue Product revenue is minimal; the HOPE Therapeutics clinics began generating early clinical revenue, but the company is pre-commercial on its drug pipeline., profitability NRx reports recurring net losses as a clinical-stage company; profitability is not expected until and unless products reach the market at scale., cash runway The cash balance has been small relative to spending, supplemented by ATM and other financings; runway is limited and a frequent focus for investors., financing / dilution An effective shelf registration and at-the-market program give flexibility to raise capital quickly, which also means ongoing dilution risk for shareholders..
The bottom line: CNS vs NRXP
CNS and NRXP are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CNS and NRXP exposure against your real portfolio. It is not an investment adviser.
Wondering how CNS or NRXP fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Cohen & Steers with AI
Connect the broker you already use and ask Walnut's AI how CNS fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between CNS and NRXP?
+
Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. NRx Pharmaceuticals, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is CNS or NRXP the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, CNS or NRXP?
+
On forward P/E (as of August 2026), CNS trades at 21.15x and NRXP at 6.30x, so NRXP is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both CNS and NRXP?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of CNS vs NRXP?
+
CNS: CNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings. Its concentration in real estate and rate-sensitive income means a reversal to higher-for-longer rates, or a rotation away from REITs and preferreds, could trigger outflows and market depreciation at the same time. The active-management fee model faces secular pressure from low-cost passive and index products, and net flows can turn negative in stressed markets. Newer private and non-traded initiatives add execution and liquidity risk, and results can be lumpy quarter to quarter. NRXP: NRXP is a speculative, cash-constrained clinical-stage biotech with minimal product revenue and a history of net losses. Its reported cash balance has been small relative to its needs, so it relies on at-the-market sales, other financings, and an effective shelf registration, all of which point to ongoing dilution risk for existing shareholders. The investment case is binary and catalyst-dependent: FDA decisions on preservative-free ketamine, clinical outcomes for NRX-101, and execution of the HOPE clinic and spin-out plan can each fail or slip. Regulatory rejection, trial disappointment, manufacturing or commercialization setbacks, litigation or arbitration outcomes, and difficulty raising capital on acceptable terms are all real hazards. The stock can be highly volatile and, like many micro-cap biotechs, carries a meaningful risk of permanent capital loss.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CNS or NRXP; figures are approximate and dated (as of August 2026). Verify current data before investing.